Laura de Jong
PhD candidate
- Name
- L.M. de Jong MSc
- Telephone
- 071 5272727
- l.m.de.jong@lacdr.leidenuniv.nl
- ORCID iD
- 0000-0001-9719-6051
PhD candidate
- Science
- Leiden Academic Centre for Drug Research
- LACDR/Pharmacology
- Hoekstra M., Jong L.M. de, Geest R. van der, Leeuw L.R. de, Krinamurthi R., Geerling J.J. & Eck M. van (2024), LXR Agonist T0901317′s hepatic impact overrules its atheroprotective action in macrophages, driving early atherogenesis in cow-diet-fed male apolipoprotein E knockout mice, Biomolecules 14(4): 429.
- Jong L.M. de, Harpal C, Berg D. van den., Hoekstra M., Peter N.J., Rissmann R., Swen J.J. & Manson M.L. (2024), CYP and non-CYP drug metabolizing enzyme families exhibit differential sensitivities towards pro-inflammatory cytokine modulation, Drug Metabolism and Disposition 52(12): 1429-1437.
- Jong L.M. de, Kreeke A.M. van de, Ahmadi M., Swen J.J., Knibbe C.A.J., Hasselt J.G.C. van, Manson M.L. & Krekels E.H.J. (2024), Changes in plasma clearance of CYP450 probe drugs may not be specific for altered in vivo enzyme activity under (patho)physiological conditions : how to interpret findings of probe cocktail studies, Clinical Pharmacokinetics 63(11): 1585-1595.
- Jong L.M. de, Boussallami S., Sánchez-López E., Giera M., Tushuizen M.E., Hoekstra M., Hawinkels L.J.A.C., Rissmann R., Swen J.J. & Manson M.L. (2023), The impact of CYP2C19 genotype on phenoconversion by concomitant medication, Frontiers in Pharmacology 14: 1201906.
- Jong L.M. de, Zhang Z., Hartog Y. de, Sijsenaar T.J.P., Martins Cardoso R., Manson M.L., Hankemeier T., Lindenburg P.W., Salvatori D.C.F., Eck M. van & Hoekstra M. (2022), PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice, Scientific Reports 12(1): 483.
- Jong L.M. de, Klomp S.D., Treijtel N., Rissmann R., Swen J.J. & Manson M.L. (2022), A systematic review on disease-drug-drug interactions with immunomodulating drugs: a critical appraisal of risk assessment and drug labelling, British Journal of Clinical Pharmacology 88(10): 4387-4402.
- Jong L.M. de, Jiskoot W., Swen J.J. & Manson M.L. (2020), Distinct effects of inflammation on Cytochrome p450 regulation and drug metabolism: lessons from experimental models and a potential role for pharmacogenetics, Genes 11(12): 1509.
- Hoekstra M., Nahon J.E., Jong L.M. de, Kröner M.J., Leeuw L.R. de & Eck M. van (2019), Inhibition of PRMT3 activity reduces hepatic steatosis without altering atherosclerosis susceptibility in apoE knockout mice, Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1865(6): 1402-1409.